PBAC's latest decision on Apomorphine hydrochloride hemihydrate: Recommended (2018). Considered for Treatment of Parkinson's disease in patients with severely disabling motor fluctuations that have not responded to other therapy.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2018
Submissions
1
2018 → 2018
Eligible population
Adults with Parkinson's disease who have experienced severely disabling motor fluctuations that have not responded to other therapy.
Therapy area
Neurology
Line of therapy
Any
Evidence base
Cost-minimisation
Economic model
Cost-minimisation
ICER note
Minor submission with no economic evaluation; cost-minimisation (no net financial impact expected)